John C. Bell

John C. Bell

Center for Innovative Cancer Research, Ottawa Hospital Research Institute (OHRI)

Affiliated withOttawa Hospital Research Institute (OHRI)

Research Area

Biography

John C. Bell has not added Biography.
If you are John C. Bell and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1
Year
<em>Ex Vivo</em> Infection of Live Tissue with Oncolytic Viruses
Publication title

Cited by 22

2011

Other Publications

Article
Year
An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

Molecular cell| PubMed ID: 12667446

2003
CHD1 associates with NCoR and histone deacetylase as well as with RNA splicing proteins.

Biochemical and biophysical research communications| PubMed ID: 12890497

2003
2003
2003
Vesicular stomatitis virus: re-inventing the bullet.

Trends in molecular medicine| PubMed ID: 15121047

2004
2004
2004
2004
Internal translation initiation mediated by the angiogenic factor Tie2.

The Journal of biological chemistry| PubMed ID: 15802272

2005
2005
2006
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 16638865

2006
2006
2006
2006
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 17164783

2007
2006
Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 17264852

2007
Oncolytic viruses: what's next?

Current cancer drug targets| PubMed ID: 17346103

2007
2007
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 17579581

2007
2007
2007
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?

Current opinion in molecular therapeutics| PubMed ID: 18228179

2008
2008
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 18281557

2008
2008
2008
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 18500240

2008
2008
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 18560417

2008
Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 18676763

2008
Development of targeted oncolytic virotherapeutics through translational research.

Expert opinion on biological therapy| PubMed ID: 18694356

2008
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 18815361

2008
2009
MicroRNAs fine-tune oncolytic viruses.

Nature biotechnology| PubMed ID: 19060871

2008
Diplomatic immunity: turning a foe into an ally.

Current opinion in molecular therapeutics| PubMed ID: 19169955

2009
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 19351762

2009
2010
Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.

International journal of cancer. Journal international du cancer| PubMed ID: 19957332

2010
Intelligent design: combination therapy with oncolytic viruses.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 20029399

2010
2010
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 20080710

2010
Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 20160706

2010
Novel oncolytic viruses: riding high on the next wave?

Cytokine & growth factor reviews| PubMed ID: 20219409

2010
United virus: the oncolytic tag-team against cancer!

Cytokine & growth factor reviews| PubMed ID: 20227326

2010
Synergistic interaction between oncolytic viruses augments tumor killing.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 20234341

2010
2010
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 20389287

2010
2010
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 20551913

2010
2010
Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 20808290

2010
2010
Targeting tumor vasculature with an oncolytic virus.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 21364541

2011
2011
Thunder and lightning: immunotherapy and oncolytic viruses collide.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 21505424

2011
2011
2011
Targeted and Armed Oncolytic Poxviruses for Cancer: The Lead Example of JX-594.

Current pharmaceutical biotechnology| PubMed ID: 21740365

2011
2011
2011
2011
Interfering with tumor pathways that augment viral oncolysis.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 22134743

2011
Oncolytic viruses: smart therapeutics for smart cancers.

Future oncology (London, England)| PubMed ID: 22149027

2012
2011
2011
2011
2012
ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 22273579

2012
Aptamer-Based Viability Impedimetric Sensor for Viruses.

Analytical chemistry| PubMed ID: 22303883

2012
Electrochemical Differentiation of Epitope-Specific Aptamers.

Analytical chemistry| PubMed ID: 22324738

2012